Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv in Stable HFrEF
NCT03447990Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of danicamtiv in heart failure with reduced ejection fraction (HFrEF), sponsored by Bristol Myers Squibb. Started Feb 2018; status: completed.
02
Drugs
danicamtiv
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03447990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447990.